Advertisement
Advertisement
AGIO
Agios Pharmaceuticals, Inc.
30.02
USDSponsored
-2.73
-8.34%
Jul 31, 15:59 UTC -4
Closed
After-Market
29.66
-0.36
-1.22%
AGIO Earnings Reports
Positive Surprise Ratio
AGIO beat 29 of 42 last estimates.
69%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$42.47M
/-$1.41
Implied change from Q2 26 (Revenue/ EPS)
-5.08%
/-16.57%
Implied change from Q3 25 (Revenue/ EPS)
+229.75%
/-20.79%
Agios Pharmaceuticals, Inc. earnings per share and revenue
On Jul 30, 2026, AGIO reported earnings of -1.69 USD per share (EPS) for Q2 26, beating the estimate of -1.70 USD, resulting in a 0.66% surprise. Revenue reached 44.74 million, compared to an expected 26.03 million, with a 71.89% difference. The market reacted with a -6.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -1.41 USD, with revenue projected to reach 42.47 million USD, implying an decrease of -16.57% EPS, and decrease of -5.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.00
Surprise
-90.05%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.13%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.46
Actual
$14.29
Surprise
+36.51%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
FibroBiologics, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.66
Surprise
+10.13%
FAQ
What were Agios Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Agios Pharmaceuticals, Inc. reported EPS of -$1.69, beating estimates by 0.66%, and revenue of $44.74M, 71.89% above expectations.
How did the market react to Agios Pharmaceuticals, Inc.'s Q2 2026 earnings?
The stock price moved down -6.46%, changed from $35.01 before the earnings release to $32.75 the day after.
When is Agios Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Agios Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.41 and revenue of $42.47M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement